Results 21 to 30 of about 793,626 (282)

Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen [PDF]

, 2019
The effectiveness of most cancer targeted therapies is short-lived. Tumors often develop resistance that might be overcome with drug combinations. However, the number of possible combinations is vast, necessitating data-driven approaches to find optimal ...
Abante, J, Abecassis, BS, Aben, N, Aghamirzaie, D, Ahsen, ME, Aittokallio, T, Akhtari, FS, Al-lazikani, B, Alam, T, Allam, A, Allen, C, Altarawy, D, Alves, V, Amadoz, A, Anchang, B, Angel Pujana, M, Antolin, AA, Ash, JR, Ba-alawi, W, Bagheri, M, Bajic, V, Ball, G, Ballester, PJ, Baptista, D, Bare, C, Bateson, M, Bender, A, Bertrand, D, Boroevich, KA, Bosdriesz, E, Bougouffa, S, Bounova, G, Brouwer, T, Bryant, B, Bulusu, KC, Calaza, M, Calderone, A, Calza, S, Capuzzi, S, Carbonell-Caballero, J, Carlin, D, Carter, H, Castagnoli, L, Celebi, R, Cesareni, G, Chang, H, Chen, G, Chen, H, Chen, H, Cheng, L, Chernomoretz, A, Chicco, D, Cho, K-H, Cho, S, Choi, D, Choi, J, Choi, K, Choi, M, Coker, E, Combinatio, A-SD, Cortes-Ciriano, I, Cserzo, M, Cubuk, C, Curtis, C, Dang, CC, de Almeida, MP, De Cock, M, de Esch, I, de Graaf, C, De Maeyer, D, De Niz, C, de Ruiter, JR, De Troyer, E, Di Veroli, GY, Dijkstra, T, Dopazo, J, Draghici, S, Drosou, A, Dry, JR, Dumontier, M, Ehrhart, F, Eid, F-E, ElHefnawi, M, Elmarakeby, H, Engin, HB, Evelo, C, Falcao, AO, Farag, S, Fawell, S, Fernandez-Lozano, C, Fisch, K, Flobak, A, Fornari, C, Foroushani, ABK, Fotso, DC, Fourches, D, Friend, S, Frigessi, A, Gao, F, Gao, X, Garnett, MJ, Gerold, JM, Gestraud, P, Ghazoui, Z, Ghosh, S, Gillberg, J, Godoy-Lorite, A, Godynyuk, L, Godzik, A, Goldenberg, A, Gomez-Cabrero, D, Gonen, M, Gray, H, Grechkin, M, Guan, Y, Guimera, R, Guinney, J, Guney, E, Haibe-Kains, B, Han, Y, Hase, T, He, D, He, L, Heath, LS, Hellton, KH, Helmer-Citterich, M, Hidalgo, MR, Hidru, D, Hill, SM, Hochreiter, S, Hong, S, Hovig, E, Hsueh, Y-C, Hu, Z, Huang, JK, Huang, RS, Hunyady, L, Hwang, J, Hwang, TH, Hwang, W, Hwang, Y, Isayev, O, Jack, J, Jahandideh, S, Jang, IS, Jeon, M, Ji, J, Jo, Y, Kamola, PJ, Kanev, GK, Kang, J, Karacosta, L, Karimi, M, Kaski, S, Kazanov, M, Khamis, AM, Khan, SA, Kiani, NA, Kim, A, Kim, J, Kim, J, Kim, K, Kim, K, Kim, S, Kim, Y, Kim, Y, Kirk, PDW, Kitano, H, Klambauer, G, Knowles, D, Ko, M, Kohn-Luque, A, Kooistra, AJ, Kuenemann, MA, Kuiper, M, Kurz, C, Kwon, M, Laegreid, A, Lederer, S, Lee, H, Lee, J, Lee, YW, Leppaho, E, Lewis, R, Li, J, Li, L, Liley, J, Lim, WK, Lin, C, Liu, Y, Lopez, Y, Low, J, Lysenko, A, Machado, D, Madhukar, N, Malpartida, AB, Mamitsuka, H, Marabita, F, Marchal, K, Marttinen, P, Mason, D, Mason, MJ, Mazaheri, A, Mehmood, A, Mehreen, A, Menden, MP, Michaut, M, Miller, RA, Mitsopoulos, C, Modos, D, Moo, K, Motsinger-Reif, A, Movva, R, Muraru, S, Muratov, E, Mushthofa, M, Nagarajan, N, Nakken, S, Nath, A, Neto, EC, Neuvial, P, Newton, R, Nguyen, T, Ning, Z, Norman, T, Oliva, B, Olsen, C, Palmeri, A, Panesar, B, Papadopoulos, S, Park, J, Park, S, Park, S, Pawitan, Y, Peluso, D, Pendyala, S, Peng, J, Perfetto, L, Pirro, S, Plevritis, S, Politi, R, Poon, H, Porta, E, Prellner, I, Preuer, K, Ramnarine, R, Reid, JE, Reyal, F, Richardson, S, Ricketts, C, Rieswijk, L, Rocha, M, Rodriguez-Gonzalvez, C, Roell, K, Romeo Aznar, V, Rotroff, D, Rukawa, P, Sadacca, B, Saez-Rodriguez, J, Safikhani, Z, Safitri, F, Sales-Pardo, M, Sauer, S, Schlichting, M, Seoane, JA, Serra, J, Shang, M-M, Sharma, A, Sharma, H, Shen, Y, Shiga, M, Shin, M, Shkedy, Z, Shopsowitz, K, Sinai, S, Skola, D, Smirnov, P, Soerensen, IF, Soerensen, P, Song, J-H, Song, SO, Soufan, O, Spitzmueller, A, Steipe, B, Stolovitzky, G, Suphavilai, C, Szalai, B, Tamayo, SP, Tamborero, D, Tang, EKY, Tang, J, Tanoli, Z-U-R, Tarres-Deulofeu, M, Tegner, J, Thommesen, L, Tonekaboni, SAM, Tran, H, Truong, A, Tsunoda, T, Turu, G, Tzeng, G-Y, Van Daele, D, van Engelen, B, van Laarhoven, T, Van Moerbeke, M, van Westen, GJP, Verbeke, L, Videla, S, Vis, D, Vogel, R, Voronkov, A, Votis, K, Walk, OBD, Wang, A, Wang, D, Wang, H-QH, Wang, P-W, Wang, S, Wang, W, Wang, X, Wang, X, Wennerberg, K, Wernisch, L, Wessels, L, Westerman, BA, White, SR, Wijayawardena, B, Willighagen, E, Wolfinger, R, Wurdinger, T, Xie, L, Xie, S, Xu, H, Yadav, B, Yau, C, Yeerna, H, Yin, JW, Yu, M, Yu, M, Yu, T, Yun, SJ, Zakharov, A, Zamichos, A, Zanin, M, Zaslavskiy, M, Zeng, L, Zenil, H, Zhang, F, Zhang, P, Zhang, W, Zhao, H, Zhao, L, Zheng, W, Zoufir, A, Zucknick, M   +354 more
core   +21 more sources

Network-based prediction of drug combinations

Nature Communications, 2019
Combination therapy holds great promise, but discovery remains challenging. Here, the authors propose a method to identify efficacious drug combinations for specific diseases, and find that successful combinations tend to target separate neighbourhoods ...
Feixiong Cheng, István A. Kovács, Albert-László Barabási   +2 more
doaj   +1 more source

A Bayesian seamless phase I-II trial design with two stages for cancer clinical trials with drug combinations

, 2020
The use of drug combinations in clinical trials is increasingly common during the last years since a more favorable therapeutic response may be obtained by combining drugs.
Jiménez, José L., Kim, Sungjin, Tighiouart, Mourad   +2 more
core   +1 more source

Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. [PDF]

, 2020
Hundreds of trials are being conducted to evaluate combination of newer targeted drugs as well as immunotherapy. Our aim was to compare efficacy and safety of combination versus single non-cytotoxic anticancer agents. We searched PubMed (01/01/2001 to 03/
Barkauskas, Donald A, De Melo Gagliato, Débora, Jardim, Denis L, Kurzrock, Razelle, Nikanjam, Mina   +4 more
core   +1 more source

Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations [PDF]

, 2014
Drug resistance, de novo and acquired, pervades cellular signaling networks (SNs) from one signaling motif to another as a result of cancer progression and/or drug intervention.
Bown, James L., Goltsov, Alexey, Goltsov, Gregory, Harrison, David J., Langdon, Simon P.   +4 more
core   +5 more sources

Time-programmable drug dosing allows the manipulation, suppression and reversal of antibiotic drug resistance in vitro [PDF]

, 2017
Multi-drug strategies have been attempted to prolong the efficacy of existing antibiotics, but with limited success. Here we show that the evolution of multi-drug-resistant Escherichia coli can be manipulated in vitro by administering pairs of ...
Cronin, Leroy, Furusawa, Chikara, Galiñanes Reyes, Sabrina Galiñanes, Horinouchi, Takaaki, Tsuda, Soichiro, Yoshida, Mari   +5 more
core   +1 more source

Anthelmintic resistance of gastrointestinal nematodes in cattle in Brazil and Argentina - current status and global perspectives [PDF]

Revista Brasileira de Parasitologia Veterinária
This review outlines the current state of anthelmintic resistance (AHR) of gastrointestinal nematodes (GINs) among cattle in Argentina and Brazil, emphasizing the economic repercussions, animal health and welfare. The analysis explores factors associated
Fernando de Almeida Borges, Alessandro Francisco Talamini do Amarante, Welber Daniel Zaneti Lopes, Candela Canton, Luis Alvarez, Adrian Lifschitz   +5 more
doaj   +1 more source

Dynamic Rearrangement of Cell States Detected by Systematic Screening of Sequential Anticancer Treatments [PDF]

, 2017
Signaling networks are nonlinear and complex, involving a large ensemble of dynamic interaction states that fluctuate in space and time. However, therapeutic strategies, such as combination chemotherapy, rarely consider the timing of drug perturbations ...
Blicher Bjerregård, Mathias, Cox, Thomas R., Erler, Janine T., Ferkinghoff-Borg, Jesper, Koplev, Simon, Linding, Rune, Longden, James, Pedersen, Jesper T., Sommer, Morten Otto Alexander, Voellmy, Franziska   +9 more
core   +3 more sources

Market research of medicinal products which are used in cardiological diseases treatment

Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki, 2017
Aim of the study is to carry out market research of medicinal products which are used in cardiological diseases treatment. Materials and methods.
O. S. Kukhtenko, L. S. Simonyan, Ye. V. Hladukh   +2 more
doaj   +1 more source

Investigating therapeutic efficacy of dacarbazine and temozolomide, alone and in combination with BRAF(V600E) siRNA in A375 human melanoma cell line [PDF]

Iranian Journal of Basic Medical Sciences
Objective(s): Melanoma is one of the most aggressive and deadly skin cancers. Despite advances, effective melanoma treatment is challenging, often requiring a shift from individual therapies to combination approaches.
Fatemeh Tabandeh, Rana Moradian Tehrani, Mohammadreza Sharifi, Elmira Toopchi   +3 more
doaj   +1 more source